Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both?

Sodium glucose cotransporter (SGLT)-2 inhibitors are the newest addition to our treatment armamentarium for the management of hyperglycemia in type 2 diabetes. Glucose-lowering per se reduces the risk of microvascular complications, but not the risk of cardiovascular disease, including heart failure...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Scholtes, Rosalie A., van Baar, Michaël J.B., Lytvyn, Yuliya, Bjornstad, Petter, Nieuwdorp, Max, Cherney, David Z.I., van Raalte, Daniël H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045873/
https://ncbi.nlm.nih.gov/pubmed/30843294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13692
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados